

257. Lavelle, R.S., *et al.* Quality of life after suprapubic catheter placement in patients with neurogenic bladder conditions. *Neurourol Urodyn*, 2016. 35: 831.
<https://pubmed.ncbi.nlm.nih.gov/26197729>
258. Hird, A.E., *et al.* Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada. *BMJ Open*, 2021. 11: e050728.
<https://pubmed.ncbi.nlm.nih.gov/34475180>
259. Hollingsworth, J.M., *et al.* Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. *Ann Intern Med*, 2013. 159: 401.
<https://pubmed.ncbi.nlm.nih.gov/24042368>
260. Ismail, S., *et al.* Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. *Neurourol Urodyn*, 2018. 37: 1386.
<https://pubmed.ncbi.nlm.nih.gov/29168217>
261. Shen, S.H., *et al.* Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis. *Int Urol Nephrol*, 2022. 54: 737.
<https://pubmed.ncbi.nlm.nih.gov/35226282>
262. Buyse, G., *et al.* Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. *J Urol*, 1998. 160: 892.
<https://pubmed.ncbi.nlm.nih.gov/9720583>
263. Di Stasi, S.M., *et al.* Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. *J Urol*, 2001. 166: 2232.
<https://pubmed.ncbi.nlm.nih.gov/11696741>
264. Giannantoni, A., *et al.* Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. *J Urol*, 2004. 172: 240.
<https://pubmed.ncbi.nlm.nih.gov/15201783>
265. Kim, J.H., *et al.* Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. *J Spinal Cord Med*, 2003. 26: 358.
<https://pubmed.ncbi.nlm.nih.gov/14992337>
266. Del Popolo, G., *et al.* Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. *Eur Urol*, 2008. 53: 1013.
<https://pubmed.ncbi.nlm.nih.gov/17950989>
267. Reitz, A., *et al.* European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. *Eur Urol*, 2004. 45: 510.
<https://pubmed.ncbi.nlm.nih.gov/15041117>
268. Yuan, H., *et al.* Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. *International Neurourology Journal*, 2017. 21: 53.
<https://pubmed.ncbi.nlm.nih.gov/28361515>
269. Cheng, T., *et al.* Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One*, 2016. 11: e0159307.
<https://pubmed.ncbi.nlm.nih.gov/27463810>
270. Wagle Shukla, A., *et al.* Botulinum Toxin Therapy for Parkinson's Disease. *Semin Neurol*, 2017. 37: 193.
<https://pubmed.ncbi.nlm.nih.gov/28511260>
271. Wu, S.J., *et al.* Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis. *Ren Fail*, 2019. 41: 937.
<https://pubmed.ncbi.nlm.nih.gov/31599184>
272. Chen, S.F., *et al.* Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury. *Toxins (Basel)*, 2022. 14.
<https://pubmed.ncbi.nlm.nih.gov/35051012>
273. Baron, M., *et al.* Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study. *J Urol*, 2019. 201: 769.
<https://pubmed.ncbi.nlm.nih.gov/30359679>
274. Leitner, L., *et al.* More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned. *Eur Urol*, 2016. 70: 522.
<https://pubmed.ncbi.nlm.nih.gov/27106070>